This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hafner, R. Articles by Drusano, G. Search for Related Content PubMed PubMed Citation Articles by Hafner, R. Articles by Drusano, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB RIFABUTIN

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2001, p. 1572-1577, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1572-1577.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Tolerance and Pharmacokinetic Interactions of Rifabutin and Azithromycin

Richard Hafner,^1,* James Bethel,² Harold C. Standiford,³ Stephen Follansbee,⁴ David L. Cohn,⁵ Ronald E. Polk,⁶ Larry Mole,⁷ Ralph Raasch,⁸ Princy Kumar,⁹ David Mushatt,¹⁰ and George Drusano^11, for the Datri 001B Study Group

Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,¹ Westat, Rockville,² and University of Maryland School of Medicine, Institute of Human Virology, and the Veterans Administration Medical Center, Baltimore,³ Maryland; Davies Medical Center, San Francisco, California⁴; Denver Public Health and University of Colorado Health Sciences Center, Denver, Colorado⁵; Virginia Commonwealth University/Medical College of Virginia Campus, Richmond, Virginia⁶; AIDS Research Center, Veterans Administration Palo Alto Health Care System, Palo Alto, California⁷; University of North Carolina at Chapel Hill, North Carolina⁸; Georgetown University, Washington, D.C.⁹; Tulane University School of Medicine, New Orleans, Louisiana¹⁰; and Albany Medical College, Albany, New York¹¹

Received 17 April 2000/Returned for modification 8 October 2000/Accepted 8 February 2001

This multicenter study evaluated the tolerance and potential pharmacokinetic interactions between azithromycin and rifabutin in volunteers with or without human immunodeficiency virus infection. Daily dosing with the combination of azithromycin and rifabutin was poorly tolerated, primarily because of gastrointestinal symptoms and neutropenia. No significant pharmacokinetic interactions were found between these drugs.

---

^* Corresponding author. Mailing address: Division of AIDS, NIAID, 6700-B Rockledge Dr.-MSC 7624, Bethesda, MD 20892-7624. Phone: (301) 402-2304. Fax: (301) 402-3171. E-mail: RHafner{at}niaid.nih.gov.

The DATRI 001B Study Group also includes Maureen Power and Karen Oseekey (DAIDS, NIAID, Bethesda, Md.); Stephanie LaCarruba (Davies Medical Center, San Francisco, Calif.); Beverly Barber (Denver Public Health, Denver, Colo.); Mark Holodniy (Veterans Administration Medical Center, Palo Alto, Calif.); Charles van der Horst (University of North Carolina, Chapel Hill, N.C.); Mary Banach, Marcia Scott, and Suzanne Beckner (Westat, Rockville, Md.); Bernard Landry, Theresa Straut, and Mary Enama (Social & Scientific Systems, Rockville, Md.); and John Pelosi (McKesson, Rockville, Md.).

---

Antimicrobial Agents and Chemotherapy, May 2001, p. 1572-1577, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1572-1577.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

• Finch, C. K., Chrisman, C. R., Baciewicz, A. M., Self, T. H. (2002). Rifampin and Rifabutin Drug Interactions: An Update. Arch Intern Med 162: 985-992 [Abstract] [Full Text]